GO
Loading...

Biotechnology

More

  • Cramer’s One-on-One with Immunogen CEO Monday, 4 Jun 2012 | 6:20 PM ET

    Daniel Junius, CEO of Immunogen, discusses drugs the company is developing.

  • Metals ETFs Attracting Safe Haven Crowd Tuesday, 29 May 2012 | 4:05 PM ET

    Investors who jumped into U.S. Treasurys and the dollar during the latest flare-up of the EU crisis appear to have expanded into gold and other metals, according to a new report.

  • Winning Equity ETFs During May EU Crisis Tuesday, 29 May 2012 | 12:42 PM ET

    A few sectors have managed to gain ground during the past three weeks, and retail investors who took advantage of the right ETFs have something to show for it.

  • How Microprocessors Are Reinventing the Prosthesis Tuesday, 29 May 2012 | 11:22 AM ET

    Faced with more service members returning without limbs from Iraq and Afghanistan, scientists, the government and private-sector companies are using new materials, tools and techniques to create sophisticated prostheses for amputees.

  • There is a great chance that Sirius XM Radio’s stock will hit $1.65 within the next several sessions — in other words, this is bound to get worse before it gets better.

  • 5 Stocks Under $10 Poised for Breakouts Thursday, 17 May 2012 | 12:50 PM ET

    Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.

  • Jobs for Loners Tuesday, 8 May 2012 | 4:44 PM ET
    In the immortal words of Barbra Streisand, people who need people are the luckiest people in the world. But what about the rest of us? We don’t all have what it takes to be gregarious, and outgoing, and one’s ability to be sociable, or lack thereof, can affect the type of employment one ends up taking.The extroverted have a bevy of jobs that let them press the flesh. There are sales, management, life coaching, and any number of other jobs that demand constant interaction with others. On the othe

    Many jobs that let reserved types work in solitude offer poor salaries and unchallenging work. But there are other careers that are stimulating, well-paying and require little human contact.

  • Cramer's Top Dividend Stocks 2012 Monday, 30 Apr 2012 | 9:27 AM ET
    Whether or not the stock market continues to rally, Jim Cramer recommends investors seek the protection of stocks with serious dividends. After all, if the stock market falls and the economy worsens, dividend-paying stocks will pay investors to wait until things get better. The "Mad Money" host especially likes “accidental high-yielders” — the stocks with small payouts that wouldn’t ordinarily offer high yields. Because of downward pressure in the markets, which has hurt their share prices, thos

    We pulled together a list of Cramer's favorite dividend plays. Read on and pick one or two for your portfolio. They could offer just the kind of defense that you need.

  • Spotlight: Energy Monday, 23 Apr 2012 | 1:05 PM ET
    Wind farm in Evia, Greece

    There are too many options but no one solution to the energy problem. Our needs are many. The current alternative energies — solar, wind, biofuels, nuclear and geothermal — all have limitations, but they're worth it until something better comes along.

  • Sanofi-Aventis CEO: We've Been Quick to Move Friday, 13 Apr 2012 | 10:50 AM ET

    Sanofi-Aventis has been quick to move before its patents on bestselling products expired, said CEO Chris Viehbacher.

  • Cramer's Growth Play on Celgene  Thursday, 12 Apr 2012 | 6:45 PM ET

    Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.

  • The Trade Behind Allergan's Pullback, Cramer  Thursday, 12 Apr 2012 | 6:25 PM ET

    Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.

  • Celgene Riding Molecular Biology 'Revolution': CEO Thursday, 12 Apr 2012 | 5:31 PM ET
    E. Coli

    Investors are suddenly hot for biotechnology, and that helps Celgene, CEO Robert Hugin told CNBC Thursday.

  • Celgene CEO on Health Care Growth  Thursday, 12 Apr 2012 | 3:20 PM ET

    The S&P Biotech Index is up more than 10 percent and Celgene is one of its biggest gainers. Robert Hugin, Celgene chairman & CEO, discusses what's driving the company's growth, including its recent acquisition of Avila Therapeutics.

  • CNBC's Seema Mody has the details on Regeneron Pharmaceuticals and Amgen releasing data on injectable drugs.

  • Most Productive Cities Tuesday, 28 Feb 2012 | 5:52 PM ET
    The Brookings Institution recently issued a report the compared per-capita gross domestic product and changes in employment data from 2010 to 2011 in 200 of the world’s largest metropolitan areas. The report found that these areas produced 48 percent of global output despite accounting for only 14 percent of the world’s population and employment.In other findings: Ninety percent of the fastest-growing economies were outside North America and western Europe; U.S. metropolitan areas outperformed t

    The Brookings Institution analyzed the financial data of the world’s largest metropolitan areas and uncovered some interesting findings. Check out which cities were the most productive.

  • Making Money Without the Speculation Rush Friday, 24 Feb 2012 | 5:32 PM ET

    Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.

  • Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.

  • 6 Stocks Unworthy of Biotech Bull Market Wednesday, 8 Feb 2012 | 10:57 AM ET

    Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.

  • Cramer Slaps a ‘Buy’ on Biogen Friday, 27 Jan 2012 | 9:02 PM ET

    Find out why he’s bullish on this biotech name.